Acc 2025: ge healthcare announces the u.s. launch of pivotal innovations that will help transform the cardiology care pathway

Chicago--(business wire)--ge healthcare (nasdaq: gehc) today announced the u.s. launch of flyrcado™ (flurpiridaz f 18) injection at the 2025 american college of cardiology (acc) annual scientific session & expo, taking place march 29-31 in chicago. additionally, the company will showcase new ai-powered innovations, reflecting its strategy to leverage ai to help increase efficiency and enable seamless integration of data across the cardiology care pathway. ge healthcare has been investing in.
GEHC Ratings Summary
GEHC Quant Ranking